Also trades as: OABI (NASDAQ) · $vol 7M
OABIW NASDAQ
OmniAb, Inc.
1W: +26.2%
1M: -22.5%
3M: +202.0%
YTD: +174.6%
1Y: -42.2%
3Y: -32.0%
$0.39
+0.15 (+61.46%)
After Hours: $0.32 (-0.07, -18.18%)
Credit Risk of going bust: lower than 56% of companies Debt: 2.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.6%), OmniAb, Inc. would be worth roughly what it owes.
Total debt $18.9M against a stock market value of $670.2M.
Distance to default 5.73 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $9.5M (short-term plus half of long-term), stock volatility 71.9%; Altman Z'' 7.26. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99.6%), OmniAb, Inc. would be worth roughly what it owes.
Total debt $18.9M against a stock market value of $670.2M.
Distance to default 5.73 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $9.5M (short-term plus half of long-term), stock volatility 71.9%; Altman Z'' 7.26. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.30
Neutral
1 bullish
2 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (57)
OmniAb to Participate in Upcoming Investor Conferences in November
OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference
OmniAb, Inc. Estimates – NASDAQ:OABIW - TradingView
OmniAb to Report Third Quarter 2026 Financial Results on October 30
OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth
OmniAb, Inc. (OABI) Analyst/Investor Day - Slideshow (NASDAQ:OABI) 2026-10-06 - Seeking Alpha
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
Bank of America Corp DE Acquires 149,493 Shares of OmniAb, Inc. $OABI
OmniAb to Host Investor & Analyst Day on October 6, 2026
Bank of New York Mellon Corp Purchases Shares of 318,406 OmniAb, Inc. $OABI
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings - Seeking Alpha
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI?
VERAXA Biotech (VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology
OmniAb to Participate in Upcoming Investor Conferences
OmniAb (NASDAQ:OABI) Sets New 12-Month High – Here’s What Happened
Why Eli Lilly (LLY) Stock Is Up Today
Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook
Top Midday Gainers
OmniAb lifts 2026 cash outlook following licensing momentum
OmniAb Raises 2026 Financial Guidance
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
OmniAb (OABI) Q2 2026 Earnings Call Transcript
Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI
Price to sales forward of OmniAb, Inc. – NASDAQ:OABIW - TradingView
OmniAb, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:OABI) 2026-08-07 - Seeking Alpha
OmniAb Q2 Earnings Call Highlights
OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ...
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
Enterprise value to revenue forward of OmniAb, Inc. – NASDAQ:OABIW - TradingView
VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
OmniAb to Report Second Quarter 2026 Financial Results on August 6
OmniAb Names Amechi Nwachuku Chief Operating Officer
The Cancer Therapy Strategy VERAXA Is Betting the Company On
OmniAb (OABI) Gains More Than 38% Over 6 Months, Can It Go Higher?
OmniAb, Inc. Warrant (OABIW) Live Share Price, Invest From India - indmoney.com
Companies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In Growth
OmniAb, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:OABI) 2026-05-11 - seekingalpha.com
OmniAb (OABI) Q1 2026 Earnings Transcript
OmniAb, Inc. Q1 2026 Earnings Call Summary
OmniAb forecasts $28M-$33M 2026 revenue as partner milestones lift outlook
Matthew Foehr Sells 19,244 Shares of OmniAb (NASDAQ:OABI) Stock
OmniAb, Inc. SEC Filing (Apr 8, 2026) - Stock Titan
OmniAb (NASDAQ:OABI) Trading 3.3% Higher – What’s Next?
Q1 Earnings Forecast for OmniAb Issued By HC Wainwright
HC Wainwright Predicts OmniAb’s Q2 Earnings (NASDAQ:OABI)
OmniAb outlines $25M–$30M 2026 revenue guidance as partner pipeline accelerates with OmniUltra and xPloration launches
Bullfrog AI (BFRGW) Stock Chart and Price History 2026 - MarketBeat
OmniAb, Inc. (OABIW) Stock Price, News, Quote & History - Yahoo! Finance Canada
OmniAb (OABIW) Stock Chart and Price History 2026 - MarketBeat
Top OmniAb (OABIW) Competitors 2026 - MarketBeat
iSpecimen (ISPC) Stock Chart and Price History 2026 - MarketBeat